<DOC>
	<DOCNO>NCT01844531</DOCNO>
	<brief_summary>The primary objective trial establish bioequivalence two fix dose combination ( FDC ) tablet ( contain medium dose empagliflozin/500 mg metformin [ Test 1 ] low dose empagliflozin/500 mg metformin [ Test 2 ] ) single tablet ( medium dose empagliflozin tablet + Glucophage® 500 mg tablet [ Reference 1 ] low dose empagliflozin tablet + Glucophage® 500 mg tablet [ Reference 2 ] ) administer together high fat , high caloric meal . The assessment safety tolerability additional objective trial .</brief_summary>
	<brief_title>Bioequivalence Empagliflozin Metformin Given Fixed Dose Combination Compared Single Tablets</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female subject 2 . Subjects must able understand comply study requirement 3 . Age 18 50 year 4 . Body mass index ( BMI ) 18.5 29.9 kg/m2 Exclusion criterion : 1 . Any relevant deviation healthy condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>